RTW Investments, LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
RTW Investments, LP disclosed 73 US equity positions worth $7.0bn in its Q2 2025 13F filing. The largest position was MDGL at 8.6% of the reported book, followed by NTRA and PTCT. Against the Q1 2025 filing, it opened 5 new positions, added to 19 and reduced 5 among the top 50 holdings.
What did RTW Investments, LP own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 8.6% | $603.4m | 1,993,687 | 0% | held |
| 2 | NTRA NATERA INC | Healthcare | 6.2% | $438.2m | 2,593,645 | 0% | held |
| 3 | PTCT PTC THERAPEUTICS INC | Healthcare | 5.4% | $378.3m | 7,746,415 | 4% | added |
| 4 | ARGX ARGENX SE | Healthcare | 5.3% | $371.2m | 673,497 | 0% | held |
| 5 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 4.5% | $318.1m | 5,756,277 | 1% | added |
| 6 | INSM INSMED INC | Healthcare | 4.4% | $310.4m | 3,084,558 | 2% | added |
| 7 | AKERO THERAPEUTICS INC | 4.2% | $292.3m | 5,477,561 | -26% | reduced | |
| 8 | VRNA VERONA PHARMA PLC | 4.1% | $288.6m | 3,051,878 | 7% | added | |
| 9 | RNAGBP AVIDITY BIOSCIENCES INC | 3.9% | $273.2m | 9,618,845 | 10% | added | |
| 10 | SYK STRYKER CORPORATION | Healthcare | 3.3% | $233.6m | 590,517 | 0% | held |
| 11 | PEN PENUMBRA INC | Healthcare | 3.2% | $221.6m | 863,553 | 0% | held |
| 12 | MERUS N V | 3.0% | $210.4m | 4,000,553 | -4% | reduced | |
| 13 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 2.8% | $194.0m | 8,995,547 | 5% | added |
| 14 | ZLAB ZAI LAB LTD | Healthcare | 2.8% | $193.6m | 5,536,876 | 77% | added |
| 15 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.3% | $158.3m | 1,516,903 | -48% | reduced |
| 16 | RDNT RADNET INC | Healthcare | 2.2% | $153.1m | 2,690,344 | 16% | added |
| 17 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.2% | $152.8m | 4,869,798 | 0% | held |
| 18 | ALKS ALKERMES PLC | Healthcare | 1.9% | $134.0m | 4,682,289 | -32% | reduced |
| 19 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.9% | $133.5m | 1,062,072 | – | new |
| 20 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.8% | $126.1m | 3,111,680 | -6% | reduced |
| 21 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.7% | $117.8m | 2,712,097 | 0% | held |
| 22 | MASI* MASIMO CORP | 1.6% | $114.9m | 683,294 | 0% | held | |
| 23 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.6% | $110.4m | 2,584,131 | 0% | held |
| 24 | ISRG INTUITIVE SURGICAL INC | Healthcare | 1.6% | $110.0m | 202,456 | 0% | held |
| 25 | CYTK CYTOKINETICS INC | Healthcare | 1.3% | $89.9m | 2,721,158 | 0% | held |
| 26 | DGX QUEST DIAGNOSTICS INC | Healthcare | 1.3% | $89.8m | 500,000 | 405% | added |
| 27 | QURE UNIQURE NV | 1.0% | $71.9m | 5,158,231 | 21% | added | |
| 28 | GHRS GH RESEARCH PLC | 1.0% | $67.5m | 5,540,457 | 1% | added | |
| 29 | URGN UROGEN PHARMA LTD | Healthcare | 0.9% | $62.3m | 4,543,895 | 18% | added |
| 30 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.9% | $62.1m | 1,707,402 | 0% | held |
| 31 | ABT ABBOTT LABS | Healthcare | 0.9% | $60.4m | 444,000 | – | new |
| 32 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.8% | $58.2m | 5,123,525 | 0% | held |
| 33 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.8% | $57.8m | 25,021,584 | 33% | added |
| 34 | SYRE SPYRE THERAPEUTICS INC | 0.8% | $54.2m | 3,621,996 | 0% | held | |
| 35 | BBNX BETA BIONICS INC | Healthcare | 0.7% | $48.0m | 3,299,191 | -0% | held |
| 36 | GEHC GE HEALTHCARE TECHNOLOGIES I | Healthcare | 0.7% | $46.4m | 626,000 | 20% | added |
| 37 | GH GUARDANT HEALTH INC | Healthcare | 0.6% | $44.6m | 856,501 | – | new |
| 38 | CGON CG ONCOLOGY INC | Healthcare | 0.6% | $44.2m | 1,701,216 | 0% | held |
| 39 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.6% | $43.3m | 17,687,772 | 0% | held |
| 40 | IMTX IMMATICS N.V | Healthcare | 0.5% | $37.5m | 6,970,152 | 1% | added |
| 41 | SLNOEUR SOLENO THERAPEUTICS INC | 0.5% | $35.6m | 424,408 | – | new | |
| 42 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.5% | $35.0m | 741,090 | – | new |
| 43 | TEM TEMPUS AI INC | Healthcare | 0.4% | $25.4m | 400,000 | 0% | held |
| 44 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.4% | $25.3m | 863,389 | 0% | held |
| 45 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.3% | $23.0m | 8,221,929 | 48% | added |
| 46 | OBIO ORCHESTRA BIOMED HLDGS INC | 0.3% | $22.3m | 8,306,062 | 1% | added | |
| 47 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.3% | $21.8m | 1,945,649 | 0% | held |
| 48 | NGNE NEUROGENE INC | 0.3% | $20.4m | 1,362,456 | 1% | added | |
| 49 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.3% | $20.1m | 1,529,836 | 2960% | added | |
| 50 | ETNBGBP 89BIO INC | 0.3% | $19.3m | 1,967,527 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.